HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 13 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Zhifei Biological Products (300122.CH) - More Downside Ahead, with Untenable Logic in HPV Vaccine

China Healthcare Weekly (Oct28)-OK Lens VBP, Time Required for Biotech to Make Profit, World Changes

Guangzhou Kingmed Diagnostics (603882CH)-Soaring Accounts Receivable/Potential Bad Debt Are Big Risk

Russia-Ukraine War Episode 2 - The Balance Could Tilt Again and Its Impact on Healthcare Industry

Interpretation of the 20th National Congress of the CPC and the Impact on China Healthcare

Innovent Biologics Inc (1801.HK) - Innovent Is Not Optional but Necessary in Portfolio

Gravity Works As WeWork Doesn't; Now Plan B

Equity Bottom-Up

Innovent Biologics Inc / Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/innovent-biologics-inc" target="_blank" data-smartkarma-citation="entities:27452:1" rel="noopener">Innovent Biologics Inc (1801 HK)</a>’s share price had some rebounds last week, which could be related to some positive progress on business and the picking-up market sentiment in healthcare sector. </li>
<li>We increased overall sales forecast for Innovent by including the two new products from Sanofi. But it’s still far from the management's target of RMB20 billion sales in 5 years.</li>
<li>Innovent’s current commercialization capability is like a "semi-finished product", and has long way to go. It lacks the second big product except PD-1 to “pave the way” for next-stage development.</li>
</ul>



Innovent Biologics Inc (1801 HK)’s share price had some rebounds last week, which could be related to some positive progress on business and the picking-up market sentiment in healthcare sector. 
We increased overall sales forecast for Innovent by including the two new products from Sanofi. But it’s still far from the management's target of RMB20 billion sales in 5 years.
Innovent’s current commercialization capability is like a "semi-finished product", and has long way to go. It lacks the second big product except PD-1 to “pave the way” for next-stage development.


Innovent Biologics Inc (1801.HK) - The Concerns and the Outlook